small molecule

NOVANTRONE

MITOXANTRONE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity

CompanyEMD Serono →See this company's full patent-cliff portfolio

Drug detail

Brand name	NOVANTRONE
Active ingredient	MITOXANTRONE HYDROCHLORIDE
Strength	EQ 20MG BASE/10ML (EQ 2MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	INJECTABLE
Route	INJECTION
Modality	Small molecule
FDA approval	December 1987
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.